Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $206.67 Average PT from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $215.83.

KRYS has been the topic of several research reports. Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup upped their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday, February 19th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently modified their holdings of KRYS. Creative Planning lifted its position in shares of Krystal Biotech by 64.9% during the 3rd quarter. Creative Planning now owns 5,744 shares of the company’s stock worth $1,046,000 after buying an additional 2,260 shares during the period. Blue Trust Inc. lifted its position in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares during the period. Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $53,000. Mount Yale Investment Advisors LLC bought a new position in shares of Krystal Biotech during the 3rd quarter worth approximately $187,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Krystal Biotech by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company’s stock valued at $184,000 after purchasing an additional 186 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 2.6 %

NASDAQ:KRYS opened at $176.39 on Thursday. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34. The business’s fifty day moving average price is $158.87 and its 200 day moving average price is $175.31. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 58.99 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the firm posted $0.30 EPS. The business’s revenue was up 116.4% compared to the same quarter last year. Equities analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).